New York 2025-2026 Regular Session

New York Assembly Bill A06927

Introduced
3/18/25  
Refer
3/18/25  

Caption

Provides that prescription labels for gonadotropin-releasing hormone agonists, pubertal suppressants, anabolic steroids, alpha reductase inhibitors, progestins, or drug classes for hormone replacement therapy maybe include the name of the dispensing practice instead of the prescriber; provides for notice to patients.

Summary

Bill A06927 amends the education law and public health law in New York to allow prescription labels for certain medications, including mifepristone, misoprostol, gonadotropin-releasing hormone agonists, pubertal suppressants, anabolic steroids, alpha reductase inhibitors, progestins, and drugs for hormone replacement therapy for gender dysphoria, to display the name or address of the dispensing healthcare practice instead of the prescriber. This change aims to enhance privacy for prescribers and potentially reduce stigma associated with these medications.

Impact

The bill modifies existing laws regarding prescription labeling, specifically for medications related to gender dysphoria and hormone therapy. By allowing the name of the healthcare practice to be displayed instead of the prescriber's name, the bill seeks to protect the identities of healthcare providers and patients, potentially influencing how prescriptions are filled and perceived in the community. This could lead to broader implications for patient confidentiality and the handling of sensitive health information.

Sentiment

The general sentiment around Bill A06927 appears to be supportive among advocates for patient privacy and those concerned with the stigma surrounding gender dysphoria treatments. However, there may be concerns from some healthcare providers regarding the implications of changing prescription labels, particularly in terms of accountability and transparency in patient care.

Contention

Notable points of contention may arise from healthcare professionals who feel that removing the prescriber's name from labels could hinder accountability and patient trust. Additionally, there may be differing opinions on the necessity of such privacy measures versus the potential risks of obscuring prescriber information, particularly in cases where patients may need to follow up on their prescriptions or seek further medical advice.

Companion Bills

NY S06422

Same As Provides that prescription labels for gonadotropin-releasing hormone agonists, pubertal suppressants, anabolic steroids, alpha reductase inhibitors, progestins, or drug classes for hormone replacement therapy maybe include the name of the dispensing practice instead of the prescriber; provides for notice to patients.

Previously Filed As

NY S10466

Provides that prescription labels for gonadotropin-releasing hormone agonists, pubertal suppressants, anabolic steroids, alpha reductase inhibitors, progestins, or drug classes for hormone replacement therapy maybe include the name of the dispensing practice instead of the prescriber; provides for notice to patients.

NY S06422

Provides that prescription labels for gonadotropin-releasing hormone agonists, pubertal suppressants, anabolic steroids, alpha reductase inhibitors, progestins, or drug classes for hormone replacement therapy maybe include the name of the dispensing practice instead of the prescriber; provides for notice to patients.

NY SB299

Modifying WV regulations on pubertal modulation, hormonal therapy, and gender reassignment

NY HB1971

AN ACT Relating to increasing access to prescription hormone therapy to patients of all ages by requiring health plans to provide reimbursement for a 12-month refill of prescription hormone therapy obtained at one time by an enrollee;

NY S4201

Authorizes coverage of prescriptive hormone replacement therapy.

NY HB5492

PRESCRIPTION HORMONE THERAPY

NY H7185

Provides that the prescription label for medication abortion prescription drugs may include the name of the dispensing healthcare practice instead of the name of the dispenser.

NY S2033

Provides that the prescription label for medication abortion prescription drugs may include the name of the dispensing healthcare practice instead of the name of the dispenser.

NY SB30

Hospitals and Related Institutions; hormone therapies and puberty-blocking medications for certain purposes to minors; prohibit prescribing or administering

NY S0578

Provides that the prescription label for medication abortion prescription drugs shall include the name of the dispensing health care practice instead of the name of the dispenser.

Similar Bills

No similar bills found.